Cognition Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cognition Therapeutics, Inc. (CGTX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$8.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-07
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$1.04M, a 269.06% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$7.57M.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $8.41M.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$5.44M, a 336.45% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $3.51M, a 89.32% increase from fiscal 2024.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.85M, a 24.02% decline from fiscal 2023.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.44M.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$749.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$8.61M 10-Q · filed 2026-08-07 | -$194.00K derived: sum of 3 quarters · filed 2026-08-07 | -$5.64M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$7.57M 10-Q · filed 2026-05-08 | $844.00K derived: sum of 2 quarters · filed 2026-05-08 | -$4.60M derived: sum of 3 quarters · filed 2026-05-08 | -$3.98M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.97M derived: sum of 2 quarters · filed 2026-03-26 | $3.58M derived: sum of 3 quarters · filed 2026-08-07 | $3.51M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$5.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.83M derived: sum of 2 quarters · filed 2026-08-07 | -$4.90M 10-Q · filed 2025-11-06 | -$6.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $614.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $539.00K 10-Q · filed 2026-08-07 | -$1.26M derived: sum of 3 quarters · filed 2026-08-07 | $1.04M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$75.00K 10-Q · filed 2026-05-08 | -$1.87M derived: sum of 2 quarters · filed 2026-05-08 | $431.00K derived: sum of 3 quarters · filed 2026-05-08 | $2.16M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $506.00K derived: sum of 2 quarters · filed 2026-03-26 | $2.23M derived: sum of 3 quarters · filed 2026-03-26 | $1.85M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.03M derived: sum of 2 quarters · filed 2025-11-06 | $3.65M 10-Q · filed 2025-11-06 | $4.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.35M 10-Q · filed 2025-08-07 | $1.95M derived: sum of 3 quarters · filed 2025-08-07 | $2.62M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$377.00K 10-Q · filed 2025-05-07 | $226.00K derived: sum of 2 quarters · filed 2025-05-07 | $898.00K derived: sum of 3 quarters · filed 2025-05-07 | $2.14M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.27M derived: sum of 2 quarters · filed 2025-03-20 | $2.52M derived: sum of 3 quarters · filed 2025-03-20 | $2.44M 10-K · filed 2025-03-20 |
| 2023-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.91M derived: sum of 2 quarters · filed 2024-11-13 | $1.84M 10-Q · filed 2024-11-13 | -$3.39M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.17M 10-Q · filed 2024-08-08 | -$4.07M derived: sum of 3 quarters · filed 2024-08-08 | $1.36M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$75.00K 10-Q · filed 2024-05-07 | -$5.31M derived: sum of 2 quarters · filed 2024-05-07 | $124.00K derived: sum of 3 quarters · filed 2024-05-07 | -$285.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$5.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $199.00K derived: sum of 2 quarters · filed 2024-03-26 | -$210.00K derived: sum of 3 quarters · filed 2024-03-26 | -$749.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $5.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.02M derived: sum of 2 quarters · filed 2023-11-02 | $4.48M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$409.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$948.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$539.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |